246 related articles for article (PubMed ID: 32359875)
1. Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019.
Gottlieb SL; Ndowa F; Hook EW; Deal C; Bachmann L; Abu-Raddad L; Chen XS; Jerse A; Low N; MacLennan CA; Petousis-Harris H; Seib KL; Unemo M; Vincent L; Giersing BK;
Vaccine; 2020 Jun; 38(28):4362-4373. PubMed ID: 32359875
[TBL] [Abstract][Full Text] [Related]
2. Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap.
Gottlieb SL; Jerse AE; Delany-Moretlwe S; Deal C; Giersing BK
Sex Health; 2019 Sep; 16(5):426-432. PubMed ID: 31476278
[TBL] [Abstract][Full Text] [Related]
3. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
[TBL] [Abstract][Full Text] [Related]
4. Planning for a Gonococcal Vaccine: A Narrative Review of Vaccine Development and Public Health Implications.
Abara WE; Jerse AE; Hariri S; Kirkcaldy RD
Sex Transm Dis; 2021 Jul; 48(7):453-457. PubMed ID: 33201019
[TBL] [Abstract][Full Text] [Related]
5. VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea.
Reyes Díaz LM; Lastre González MSJB; Cuello M; Sierra-González VG; Ramos Pupo R; Lantero MI; Harandi AM; Black S; Pérez O
Pediatr Infect Dis J; 2021 Apr; 40(4):375-381. PubMed ID: 33591079
[TBL] [Abstract][Full Text] [Related]
6. An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol.
Thng C; Semchenko EA; Hughes I; O'Sullivan M; Seib KL
BMC Public Health; 2023 Mar; 23(1):607. PubMed ID: 36997957
[TBL] [Abstract][Full Text] [Related]
7. Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022.
Prudden HJ; Achilles SL; Schocken C; Broutet N; Canfell K; Akaba H; Basu P; Bhatla N; Chirenje ZM; Delany-Moretlwe S; Denny L; Gamage DG; Herrero R; Hutubessy R; Villa LL; Murillo R; Schiller JT; Stanley M; Temmerman M; Zhao F; Ogilvie G; Kaslow DC; Dull P; Gottlieb SL;
Vaccine; 2022 Sep; 40(41):5843-5855. PubMed ID: 36008233
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Proteomics of the 2016 WHO
El-Rami FE; Zielke RA; Wi T; Sikora AE; Unemo M
Mol Cell Proteomics; 2019 Jan; 18(1):127-150. PubMed ID: 30352803
[TBL] [Abstract][Full Text] [Related]
9. Neisseria gonorrhoeae vaccine development: hope on the horizon?
Edwards JL; Jennings MP; Seib KL
Curr Opin Infect Dis; 2018 Jun; 31(3):246-250. PubMed ID: 29601324
[TBL] [Abstract][Full Text] [Related]
10. Biological feasibility and importance of a gonorrhea vaccine for global public health.
Vincent LR; Jerse AE
Vaccine; 2019 Nov; 37(50):7419-7426. PubMed ID: 29680200
[TBL] [Abstract][Full Text] [Related]
11. Vaccine value profile for Neisseria gonorrhoeae.
Lyu Y; Choong A; Chow EPF; Seib KL; Marshall HS; Unemo M; de Voux A; Wang B; Miranda AE; Gottlieb SL; Mello MB; Wi T; Baggaley R; Marshall C; Abu-Raddad LJ; Abara WE; Chen XS; Ong JJ
Vaccine; 2023 Dec; ():. PubMed ID: 38123397
[TBL] [Abstract][Full Text] [Related]
12. The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae.
Semchenko EA; Tan A; Borrow R; Seib KL
Clin Infect Dis; 2019 Sep; 69(7):1101-1111. PubMed ID: 30551148
[TBL] [Abstract][Full Text] [Related]
13. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study.
Unemo M; Lahra MM; Escher M; Eremin S; Cole MJ; Galarza P; Ndowa F; Martin I; Dillon JR; Galas M; Ramon-Pardo P; Weinstock H; Wi T
Lancet Microbe; 2021 Nov; 2(11):e627-e636. PubMed ID: 35544082
[TBL] [Abstract][Full Text] [Related]
14. The potential utility of liposomes for
Christodoulides M; Humbert MV; Heckels JE
Expert Rev Vaccines; 2021 Oct; 20(10):1235-1256. PubMed ID: 34524062
[TBL] [Abstract][Full Text] [Related]
15. Potent
Edwards JL; Balthazar JT; Esposito DLA; Ayala JC; Schiefer A; Pfarr K; Hoerauf A; Alt S; Hesterkamp T; Grosse M; Stadler M; Golparian D; Unemo M; Read TD; Shafer WM
mSphere; 2022 Oct; 7(5):e0036222. PubMed ID: 36094073
[TBL] [Abstract][Full Text] [Related]
16. Promising developments in gonococcal vaccines.
Waltmann A; Chen JS; Duncan JA
Curr Opin Infect Dis; 2024 Feb; 37(1):63-69. PubMed ID: 38050729
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to
Belcher T; Rollier CS; Dold C; Ross JDC; MacLennan CA
Front Immunol; 2023; 14():1248613. PubMed ID: 37662926
[No Abstract] [Full Text] [Related]
18. Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.
Gottlieb SL; Giersing BK; Hickling J; Jones R; Deal C; Kaslow DC;
Vaccine; 2019 Nov; 37(50):7408-7418. PubMed ID: 29224963
[TBL] [Abstract][Full Text] [Related]
19. Microencapsulated IL-12 Drives Genital Tract Immune Responses to Intranasal Gonococcal Outer Membrane Vesicle Vaccine and Induces Resistance to Vaginal Infection with Diverse Strains of Neisseria gonorrhoeae.
Liu Y; Hammer LA; Daamen J; Stork M; Egilmez NK; Russell MW
mSphere; 2023 Feb; 8(1):e0038822. PubMed ID: 36537786
[TBL] [Abstract][Full Text] [Related]
20. Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014.
Kirkcaldy RD; Harvey A; Papp JR; Del Rio C; Soge OO; Holmes KK; Hook EW; Kubin G; Riedel S; Zenilman J; Pettus K; Sanders T; Sharpe S; Torrone E
MMWR Surveill Summ; 2016 Jul; 65(7):1-19. PubMed ID: 27414503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
